Trial Profile
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2023
Price :
$35
*
At a glance
- Drugs Trichostatin A (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Vanda Pharmaceuticals
- 13 Dec 2022 Initial results (N-12) assessing the safety and efficacy of Trichostatin-A presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 07 Nov 2018 According to a Vanda Pharmaceuticals media release, first patient was randomised in this trial in October 2018.
- 07 Nov 2018 Status changed from planning to recruiting, as reported in the Vanda Pharmaceuticals media release.